BlueStone Venture Partners

GT Medical Technologies, Inc. is a medical device company dedicated to enhancing the treatment of brain tumors. Founded in 2017 and based in Tempe, Arizona, the company has developed GammaTile, an innovative device that integrates a conformable collagen matrix with brachytherapy seeds. This biocompatible technology aims to address the limitations of existing treatments for recurrent brain tumors. GammaTile has shown potential to transform care for approximately 176,000 patients annually in the United States. The product is protected by multiple patents in the U.S., Canada, and Europe, highlighting its unique design and therapeutic promise. Clinical trials conducted at the Barrow Neurological Institute have demonstrated notable clinical improvements in patients treated with GammaTile, positioning GT Medical Technologies as a significant player in the healthcare industry focused on brain tumor management.

Elucid, located in the Boston biotech and medtech hub, specializes in enhancing the accuracy and cost-effectiveness of cardiovascular diagnostic imaging through machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography (CTA) scan, aiding in the assessment of heart attack and stroke risk as well as treatment selection. The company also collaborates with pharmaceutical firms, healthcare providers, and research organizations to offer quantitative image analysis services. By applying artificial intelligence to vascular diagnostics, Elucid aims to improve patient outcomes while providing a non-invasive and economically efficient means of capturing critical health information, thereby supporting cardiovascular pathologists in delivering comprehensive clinical insights.

Akadeum Life Sciences, Inc. is a life sciences company based in Ann Arbor, Michigan, founded in 2014. The company specializes in manufacturing microbubble cell separation products designed to facilitate the removal of target cells from biological samples. Its product line includes T cell and B cell isolation kits for both human and mouse cells, as well as products for red blood cell depletion. Akadeum utilizes buoyancy-activated cell sorting technology, employing microscopic microbubbles that capture target cells and float them to the surface for efficient removal. This innovative approach enhances the efficiency of downstream testing and analysis for medical practitioners. The company's products are available for purchase online, and it maintains a strategic partnership with Agilent Technologies.

Elucid, located in the Boston biotech and medtech hub, specializes in enhancing the accuracy and cost-effectiveness of cardiovascular diagnostic imaging through machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography (CTA) scan, aiding in the assessment of heart attack and stroke risk as well as treatment selection. The company also collaborates with pharmaceutical firms, healthcare providers, and research organizations to offer quantitative image analysis services. By applying artificial intelligence to vascular diagnostics, Elucid aims to improve patient outcomes while providing a non-invasive and economically efficient means of capturing critical health information, thereby supporting cardiovascular pathologists in delivering comprehensive clinical insights.

GT Medical Technologies, Inc. is a medical device company dedicated to enhancing the treatment of brain tumors. Founded in 2017 and based in Tempe, Arizona, the company has developed GammaTile, an innovative device that integrates a conformable collagen matrix with brachytherapy seeds. This biocompatible technology aims to address the limitations of existing treatments for recurrent brain tumors. GammaTile has shown potential to transform care for approximately 176,000 patients annually in the United States. The product is protected by multiple patents in the U.S., Canada, and Europe, highlighting its unique design and therapeutic promise. Clinical trials conducted at the Barrow Neurological Institute have demonstrated notable clinical improvements in patients treated with GammaTile, positioning GT Medical Technologies as a significant player in the healthcare industry focused on brain tumor management.

Pyx Health, Inc. is a healthcare IT company based in Tucson, Arizona, with an additional office in Phoenix. Founded in 2017, the company develops a mobile solution aimed at reducing loneliness and social isolation among vulnerable populations. Its primary offering, Pyx Health, features Pyxir, a chatbot that engages users throughout their healthcare journey, fostering healthy interactions and building trusted companionship. By combining artificial intelligence with human interventions, Pyx Health provides timely support and addresses social determinants of health, particularly during crucial transitions in care. The platform ensures that members receive care and resources when they are most vulnerable, enhancing their overall wellbeing and connectivity.

Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment.

GT Medical Technologies, Inc. is a medical device company dedicated to enhancing the treatment of brain tumors. Founded in 2017 and based in Tempe, Arizona, the company has developed GammaTile, an innovative device that integrates a conformable collagen matrix with brachytherapy seeds. This biocompatible technology aims to address the limitations of existing treatments for recurrent brain tumors. GammaTile has shown potential to transform care for approximately 176,000 patients annually in the United States. The product is protected by multiple patents in the U.S., Canada, and Europe, highlighting its unique design and therapeutic promise. Clinical trials conducted at the Barrow Neurological Institute have demonstrated notable clinical improvements in patients treated with GammaTile, positioning GT Medical Technologies as a significant player in the healthcare industry focused on brain tumor management.

BroadSpot Imaging Corporation is developing a suite of diagnostic medical devices for eye care. They leverage advanced imaging technologies and small-scale, cloud-connected electronics to replace bulky, expensive diagnostic instruments with cost-effective handheld instruments and a series of valuable services. their technologies will fundamentally improve how eye care is delivered worldwide: eye doctors can see patients more efficiently, for less money, and more patients will gain access to high quality diagnostics as the population ages.